Santhera Signs a Pre-Clinical Research Agreement with Biozentrum to Advance Gene Therapy for Congenital Muscular Dystrophy

 Santhera Signs a Pre-Clinical Research Agreement with Biozentrum to Advance Gene Therapy for Congenital Muscular Dystrophy

Santhera Reports Submission of Marketing Authorization Application to the EMA for Puldysa (Idebenone) in Duchenne Muscular Dystrophy

Shots:

  • Santhera enters into a collaboration with Biozentrum, University of Basel to explore the feasibility of the gene therapy by standard viral vectors for LAMA2 MD or MDC1A, co-financed by Innosuisse of ~$1.19M
  • The focus of the collaboration is to foster Santhera’s neuromuscular pipeline and to utilize Biozentrum’s gene therapy in its Omigapil for improving its benefits in LAMA2 deficient MD
  • Biozentrum’s gene therapy utilizes two linker proteins derived from agrin, laminin and nidogen leading to a restoration of muscle fiber, recovery of muscle force and size and increases body weight. Omigapil is a deprenyl-analog, exclusively licensed from Novartis by Santhera for CMD

Click here to read full press release/ article | Ref: Santhera | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post